A clinical trial of ABCL575.
Latest Information Update: 26 Aug 2024
At a glance
- Drugs ABCL 575 (Primary)
- Indications Alopecia areata; Asthma; Atopic dermatitis; Hidradenitis suppurativa
- Focus Adverse reactions
- 26 Aug 2024 New trial record
- 06 Aug 2024 According to Abcellera media release, Clinical Trial Application (CTA) for this clinical trial is anticipated in the second quarter of 2025.